Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) covers the month of April 2019, with the report signed on April 11, 2019. The filing serves as a Final Director's Interest Notice submitted to the Australian Securities Exchange (ASX) and incorporated into U.S. SEC registration statements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director interests and does not contain financial performance data.
Material Changes
The primary material change disclosed is the cessation of Dr. George Mihaly's role as a director of the company, effective April 8, 2019. The filing details his remaining relevant interests in the company's securities at the time of departure.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports on the director's securities holdings.
Important Facts for Investors
- Director Departure: Dr. George Mihaly ceased to be a director on April 8, 2019.
- Outstanding Options: Upon departure, Dr. Mihaly held 1,250,000 unlisted options.
- Option Terms: The options are exercisable at A$0.11 per share on or before December 14, 2022.
- Other Interests: The director reported no relevant interests in securities where he was not the registered holder and no interests in contracts.